Should Medicare be allowed to square off with pharma on drug prices? Presidential candidate Hillary Clinton was the latest politician to propose it, joining Democratic rival Sen. Bernie Sanders, President Obama--and a variety of other lawmakers before them.
Presidential candidate Hillary Clinton unloaded on both the drug and insurance industries on Tuesday with proposals to help protect consumers from rapidly escalating drug prices. While most are unlikely to ever become a reality, the suggestions for price caps on consumer copays and a mandate on what drugmakers must spend on R&D turned up the heat on the debate over rising prices.
In the land of pharma, off-patent drugs usually translate to lost profits. But things don't always shake out that way, according to a new report from EvaluatePharma, which found that companies with aging blockbusters could be set to collect billion-dollar sales for the meds by 2020.
Novo Nordisk will step up its operations in Iran, saying today it will build a €70 million ($78.1 million) plant to produce its FlexPen prefilled devices to better supply the country with its insulin products.
On Monday, Hillary Clinton spooked biotech investors with a tweet promising to crack down on high drug prices. Shares plummeted. On Tuesday, she'll publicly unveil her pricing proposals in an Iowa speech, but until then, her campaign has offered some quick hints.
Valeant is famous for wringing cost savings out of its buyouts, and its tax-advantaged Canadian domicile helps on that front. Now, it's leveraging another address to pare down Salix's tax bill by more than $560 million. But how?
New court documents in the first trial over claims that Johnson & Johnson promoted its blockbuster painkiller, Tylenol, without disclosing potentially dangerous side effects show that J&J's McNeil Consumer Healthcare unit planned to lobby government officials to prevent the FDA from implementing safety restrictions, ProPublica reports.
This could go down in pharma history as the week that drug pricing met pop culture. But this week won't be remembered as the one when drugmakers lost their long-standing pricing power in the U.S. That, at least, was the word from analysts and at least one top pharma CEO as politicians vowed a crackdown.
Some heavy-hitting HIV activists have signed on to Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with the disease.
The ongoing controversies over rising drug prices have most Americans blaming drugmakers for their own rising pharmacy bills. The last thing pharma needs right now is a scandalous price hike to turn up the heat even further. But that's just what Turing Pharma and its CEO, Martin Shkreli, have on offer.
Rheumatoid arthritis therapy Xeljanz hasn't gotten off to the start Pfizer hoped, but new indications could give it a boost. On that front, the company reported positive results on Monday from a pair of trials evaluating the med in ulcerative colitis.
Change is coming for Bayer--and with it, change at the top. The German pharma has outlined its plans for retooling, post-plastics division divestment--and they involve three operational arms, each headed up by a company vet.
Senator, and presidential candidate, Bernie Sanders and his cohort, Rep. Elijah Cummings, have gotten a lot of attention for their proposed legislation to cut spiraling drug prices in the U.S. One person who seems to have noticed is Hillary Clinton, who says she will unveil her own plan this week for controlling the "cost of skyrocketing prescription drugs."
Big Pharma is having a dealmaking fiesta in Mexico, with companies such as Sanofi, Pfizer and Teva Pharmaceutical Industries considering buying local generic drugmaker Representaciones e Investigaciones Medicas, also known as Rimsa, to beef up business south of the border.
The CEO of Intas Pharmaceuticals expects his company to get FDA approval this year for its biosimilar of Amgen's Neulasta, a drug it developed with Canada's Apotex.
China's economy is a mess and other emerging markets are flailing about as well. So what is pharma CEO to do if they have bet big on growth in the EM realm? Keep on keeping on, says Novartis CEO Joe Jimenez.
Perrigo CEO Joseph Papa has cautioned investors against taking up an offer from hostile suitor Mylan. But Papa is already a Mylan shareholder himself.
For years, Pfizer has shrugged off claims that its antidepressant Zoloft causes heart defects in newborns, fighting a raft of litigation alleging that the company did not adequately warn pregnant women taking the med about its potential risks. Now the FDA is weighing in on the issue, asking the company to acknowledge some studies that link Zoloft to heart defects in babies.
On Thursday, Allergan snagged FDA approval for a sort-of-new antipsychotic, Vraylar, to treat schizophrenia and bipolar disorder in adults. But after about a two-year delay in which a raft of antipsychotics--both generic and branded--have made it to market, the question is where it will find a place of its own.
Since Eli Lilly and Boehringer Ingelheim announced that their SGLT2 med, Jardiance, had become the first to show it could lower the risk of major cardiovascular events, the question on the minds of industry watchers has been "How much?"